Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07223502 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease
A Phase 3 study of Hypertension (HTN), sponsored by Sarfez Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07223502 is a Phase 3 study of Hypertension (HTN) that is actively recruiting participants, run by Sarfez Pharmaceuticals. The registered enrollment target is 30 participants, below the 2,177-participant average among 3 other Hypertension (HTN) trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07223502, a Phase 3 study of Hypertension (HTN), is actively recruiting participants, sponsored by Sarfez Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
A study Comparing the Clinical Benefit of Finerenone Versus a Fixed-Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients with Hypertension and Chronic Kidney Disease.
Conditions Studied
Interventions
- DRUG Combination Product: FDC of spironolactone and ER torsemide
- DRUG Combination Product: Stabilized doses of loop diuretic and finerenone
Study Locations (1)
Virginia
- Sarfez Pharmaceuticals, Inc. - Vienna
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-12-01 |
| Est. Completion | 2026-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07223502
The ClinicalTrials.gov registry entry for NCT07223502 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,177-participant average among 3 other Hypertension (HTN) trials with a reported enrollment target (99% lower). The listed sponsor is Sarfez Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension (HTN) appearing as the primary indexed condition, and to 2 interventions - of which Combination Product: FDC of spironolactone and ER torsemide is the first listed.
NCT07223502 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT07223502 about?
NCT07223502 is a clinical study titled "A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease". A study Comparing the Clinical Benefit of Finerenone Versus a Fixed-Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients with Hypertension and Chronic Kidney Disease.
What is the current status of trial NCT07223502?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2025-12-01. Estimated completion is 2026-10.
What conditions does trial NCT07223502 study?
This clinical trial studies the following conditions: Hypertension (HTN).
What interventions are being tested in trial NCT07223502?
The interventions under investigation include: Combination Product: FDC of spironolactone and ER torsemide (DRUG), Combination Product: Stabilized doses of loop diuretic and finerenone (DRUG).
Who is sponsoring clinical trial NCT07223502?
This trial is sponsored by Sarfez Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07223502 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension (HTN)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Implementation of Intensive Hypertension Management Approaches: Cleveland Clinic
RECRUITING
-
Study of the Progression of Chronic Cardiovascular Conditions
RECRUITING
-
Mediterranean-DASH Intervention for Neurodegenerative Delay and High-Intensity Interval Training in Adults With Hypertension
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.